COMPANY PROFILE

Tern Therapeutics

Pioneering one-time gene therapy treatments for rare diseases with a focus on ocular manifestations of CLN2 Batten disease

Washington DC, United StatesFounded 2023Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Tern Therapeutics

Tern Therapeutics is a biotechnology company dedicated to developing one-time gene therapy treatments for rare diseases. The company's lead candidate, TTX 381, is currently in clinical testing for the treatment of ocular manifestations of CLN2, a form of Batten disease. Tern Therapeutics operates in the rare disease market, focusing on patients and their families who are in urgent need of transformative treatments. The business model revolves around scientific, regulatory, and commercial innovation to deliver cutting-edge treatments efficiently. Revenue is generated through the development and commercialization of these gene therapies, supported by financing rounds and partnerships with healthcare institutions. The company is committed to integrity, empathy, urgency, innovation, and determination in its mission to improve the lives of patients worldwide.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: Washington DC, United States
Employees: 6
Open positions: None listed
Dealroom signal: 25.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Gene Therapy, Disease, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Aug 2024	$15M	$60M	ATW Partners	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Tern Therapeutics website traffic

Latest recorded traffic for Tern Therapeutics is 1.9K monthly website visits, up 46.2% over the last three months.

Latest monthly visits1.9K 3-month web change+46.2%

Monthly website visitsSep 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BTBrink TherapeuticsUnlocking in vivo cell therapy with the next generation of gene editing technology	Saint-Mandé, France	Operational	12	$3.9M	$15M
CPCPTxAt CPTx, new treatment paradigms are developed to address unmet medical challenges, with an initial focus on infectious diseases	Planegg, Germany	Operational
NANabGenEnabling gene therapies through antibody suppression	Durham, United States	Operational
LBLingyi BiotechnologyA leading gene therapy company with a world-leading rare disease animal model functional verification platform	Huangpu, China	Operational
GEGenespireDeveloping efficient gene therapies for people with inherited metabolic diseases and primary immunodeficiencies	Milan, Italy	Operational
BPBioTx PharmaceuticalsBiotech & Life Sciences	United Arab Emirates	Operational
AIApriligen, Inc.A clinical-stage gene therapy platform using a lentiviral vector to treat rare pediatric diseases like Diamond Blackfan Anemia	—	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational